Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA approves new drug for advanced head and neck squamous cell carcinoma

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.

FDA approves new drug for advanced head and neck squamous cell carcinoma

The U.S. Food and Drug Administration has granted approval to Janssen Biotech's Rybrevant Faspro, a new drug for treating adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after receiving platinum-based chemotherapy and immunotherapy. This marks the first approval in ten years for a medication addressing recurrent or metastatic HNSCC in patients who have undergone platinum-based chemotherapy.

Rybrevant Faspro is not intended for the treatment of oropharyngeal squamous cell carcinoma linked to human papillomavirus.

The approval is based on a clinical trial involving 102 patients with recurrent or metastatic HNSCC. The drug demonstrated an overall response rate of 42%, compared to 20% for existing therapies. Among those who responded to Rybrevant Faspro, 56% maintained a response lasting six months or longer. Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, highlighted that this approval represents a significant advancement for patients with HNSCC, a disease that has historically faced limited treatment options and poorer outcomes.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Wednesday 18 November →